An observational study in Major Depressive Disorder (MDD), sponsored by Yale University. Not yet recruiting at 2 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by Yale University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Depressive Disorder, Major by Yale University — 5 open to participants now, 8 under way, none of them phase 3. Depressive Disorder, Major · Yale University.
Among the 22 studies in Depressive Disorder, Major by Yale University, this one is the only one that started in 2026, is one of 6 observational ones, and was the 22nd registered.
3,047 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →5 of the 22 studies in Depressive Disorder, Major by Yale University are open now, in 1 country. Recruiting first, the newest first:
Yale University · Sites in United States
Ages 40–80 · Healthy volunteers
Yale University · Sites in United States
Yale University · Sites in United States
Ages 18–60
Yale University · Sites in United States
Ages 21–65
By country, each count listing its studies:
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 1 · Phase 4 1
First in 2002; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 132 across 403 observational studies indexed under Depressive Disorder, Major.
Median enrollment 30 across the 16 interventional studies, 65 across the 6 observational. Of the 13 that completed or were terminated, 6 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
Yale University is the lead sponsor of 1,772 studies on the registry; 296 are open to participants now.
Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.
2 of the studies in Depressive Disorder, Major by Yale University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02734602Yale UniversityImaging SV2A in Mood Disorders | 2027-01 |
| NCT07792252Yale UniversityREWIRE: Real-world Engagement With Interventional and Rejoyn Effectiveness | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies in Depressive Disorder, Major by Yale University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Rejoyn is a Prescription Digital Therapeutic (PDT) for adults with Major Depressive Disorder (MDD). This study aims to evaluate the feasibility, engagement, and clinical context of integrating Rejoyn into standard interventional workflows at the Yale New Haven Hospital Interventional Psychiatry Service (IPS). This is a non-significant risk, observational real-world evidence (RWE) study.
This study is only recruiting internally from among established patients and does not accept external participants.
Adults diagnosed with MDD who are receiving intranasal esketamine or TMS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rejoyn is a 510(k)-cleared Prescription Digital Therapeutic (PDT) for adults with Major Depressive Disorder (MDD) as an adjunct to clinician-managed treatment. The Rejoyn program includes 6 weeks of active Emotional Faces Memory Task (EFMT) training and Cognitive Behavioral Therapy (CBT) exercises, followed by an additional 6 weeks of access to the CBT content for additional review.
Device: Rejoyn · Behavioral: Cognitive Behavioral Therapy (CBT) exercises
Rejoyn is a 510(k)-cleared Prescription Digital Therapeutic (PDT) for adults with Major Depressive Disorder (MDD) as an adjunct to clinician-managed treatment.
Cognitive Behavioral Therapy (CBT) exercises, followed by an additional 6 weeks of access to the CBT content for additional review.
Number of patients prescribed Rejoyn
Number of patients prescribed Rejoyn out of all eligible patients in the clinic
Time frame: From screening through enrollment, approximately 1 week
Mean participant app use to assess engagement
Mean number of times app was engaged
Time frame: up to Week 12
Mean duration of app use to assess engagement
Mean duration in minutes of app use
Time frame: up to Week 12
Mean number lessons completed to assess engagement
Mean number lessons completed
Time frame: up to Week 12
Number of participants adherent to Rejoyn
Adherence defined as completion of at least 12 of the 18 sessions
Time frame: up to Week 12
Change in Montgomery Asberg Depression Rating Scale (MADRS) score
A 10-item rating scale assessing symptoms of depression. The score ranges from 0 (no depression) to 60 (very depressed).
Time frame: baseline, 2 weeks, 4 weeks, 6 weeks, and 12 weeks
Change in Quick Inventory of Depressive Symptomatology (QIDS) score
A 16-item self-reported rating scale designed to assess severity of depressive symptoms. Scores range from 0 to 27, with higher scores indicating greater depression.
Time frame: baseline, 2 weeks, 4 weeks, 6 weeks, and 12 weeks
Mean mHealth Satisfaction Questionnaire score
Satisfaction Questionnaire to assess participant satisfaction. Scores range from 1 to 5, with higher scores indicating more satisfaction.
Time frame: baseline and 12-weeks
Number of clinicians that completed the Clinician Feasibility & Workflow Questionnaire
Number of clinicians who referred patients to Rejoyn that complete the Clinician Feasibility \& Workflow Questionnaire at the end of the study
Time frame: Week 12
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Mar 2027, 6 months later.
Of 121 non-industry observational studies under Depressive Disorder, Major, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 73. This study's planned 6 months is below that.
Counting every sponsor, half of 150 studies reached it within 38 months; a quarter within 21 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.